TGR BioSciences
Melbourne, Australia· Est.
Australian immunoassay specialist offering fast, multiplexable CaptSure™ platforms for drug discovery and diagnostics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $8M
AI Company Overview
Australian immunoassay specialist offering fast, multiplexable CaptSure™ platforms for drug discovery and diagnostics.
OncologyImmunology
Technology Platform
CaptSure™ is a patented antibody immobilisation system that or rapid, no‑wash immunoassays across bead‑based, ELISA, lateral flow, IHC, and microfluidic formats.
Opportunities
Expansion of multiplex assay panels and entry into clinical diagnostics via licensing agreements provide strong growth avenues.
Risk Factors
Intense competition from established immunoassay vendors and reliance on a limited customer base could constrain revenue scaling.
Competitive Landscape
TGR competes with Meso Scale Discovery, Luminex, and Thermo Fisher, differentiating through its CaptSure™ chemistry that offers faster, simpler workflows.